Marchi E, Vargas F S, Teixeira L R, Fagundes D J, Silva L M, Carmo A O, Light R W
The Faculty of Medicine of the University of Sao Paulo, the Escola Paulista de Medicina (Brazil).
Eur Respir J. 1997 Mar;10(3):598-602.
We have previously shown that the intrapleural injection of mitozantrone but not bleomycin resulted in pleural fibrosis. Mechlorethamine hydrochloride (nitrogen mustard) was used extensively in the past to control malignant effusions, with relatively good success. The objective of this study was to determine if the intrapleural injection of nitrogen mustard would produce pleural sclerosis in our experimental model in rabbits. We therefore evaluated sclerosing capabilities of nitrogen mustard as well as those of cytarabine and dacarbazine. Nitrogen mustard (0.4 and 0.8 mg x kg(-1)), cytarabine (3, 6 and 20 mg x kg(-1)) and dacarbazine (4, 8 and 20 mg x kg(-1)) were instilled intrapleurally into anaesthetized rabbits. Twenty eight days after the instillation, the animals were killed, and the pleural spaces were assessed grossly for evidence of pleurodesis and microscopically for evidence of fibrosis and inflammation. The intrapleural injection of 0.8 mg x kg(-1) nitrogen mustard was effective in creating pleural fibrosis, either grossly or microscopically. The mean degree (scale 0-4) of gross pleurodesis in the rabbits that received 0.8 mg x kg(-1) nitrogen mustard was 3.2+/-1.0 and the mean degree of microscopic pleural fibrosis was 3.5+/-0.8. The intrapleural injection of 0.4 mg x kg(-1) nitrogen mustard and the different doses of cytarabine (3, 6 and 20 mg x kg(-1)) and dacarbazine (4, 8 and 20 mg x kg(-1)) were ineffective in producing pleurodesis. From this study, we conclude that the intrapleural injection of 0.8 mg x kg(-1) of nitrogen mustard produces clinically significant pleurodesis in rabbits. Consideration should be given to future clinical studies utilizing 0.6-0.8 mg x kg(-1) nitrogen mustard intrapleurally for the treatment of malignant pleural effusion.
我们之前已经表明,胸膜腔内注射米托蒽醌而非博来霉素会导致胸膜纤维化。盐酸氮芥(氮芥)过去被广泛用于控制恶性胸腔积液,取得了相对较好的成效。本研究的目的是确定在我们的兔实验模型中,胸膜腔内注射氮芥是否会产生胸膜粘连。因此,我们评估了氮芥以及阿糖胞苷和达卡巴嗪的硬化能力。将氮芥(0.4和0.8毫克/千克)、阿糖胞苷(3、6和20毫克/千克)和达卡巴嗪(4、8和20毫克/千克)经胸膜腔内注入麻醉的兔体内。注入28天后,处死动物,大体评估胸膜腔有无胸膜粘连的证据,显微镜下评估有无纤维化和炎症的证据。胸膜腔内注射0.8毫克/千克氮芥在大体或显微镜下均能有效造成胸膜纤维化。接受0.8毫克/千克氮芥的兔的大体胸膜粘连平均程度(0 - 4级)为3.2±1.0,显微镜下胸膜纤维化平均程度为3.5±0.8。胸膜腔内注射0.4毫克/千克氮芥以及不同剂量的阿糖胞苷(3、6和20毫克/千克)和达卡巴嗪(4、8和20毫克/千克)均不能有效产生胸膜粘连。从本研究中,我们得出结论,胸膜腔内注射0.8毫克/千克氮芥可在兔体内产生具有临床意义的胸膜粘连。应考虑未来进行临床研究,采用0.6 - 0.8毫克/千克氮芥胸膜腔内注射治疗恶性胸腔积液。